Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).

about

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).

Item

http://www.wikidata.org/entity/Q37747750

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 April 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).

@en

Preoperative imatinib mesylate

@nl

type

Item

label

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).

@en

Preoperative imatinib mesylate

@nl

prefLabel

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).

@en

Preoperative imatinib mesylate

@nl

P1476

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).

@en

P2093

Bo Zhang

http://www.w3.org/2001/XMLSchema#string

Chaoyong Shen

http://www.w3.org/2001/XMLSchema#string

Jiaju Chen

http://www.w3.org/2001/XMLSchema#string

Jinliang Yang

http://www.w3.org/2001/XMLSchema#string

Sumin Tang

http://www.w3.org/2001/XMLSchema#string

Xiaonan Yin

http://www.w3.org/2001/XMLSchema#string

Yuan Yin

http://www.w3.org/2001/XMLSchema#string

Yuqin Yao

http://www.w3.org/2001/XMLSchema#string

Zhixin Chen

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Neoadjuvant imatinib for borderline resectable GIST.

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.

The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

P2888

s12957-017-1143-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-017-1143-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084737940

http://www.w3.org/2001/XMLSchema#string

P698

28399894

http://www.w3.org/2001/XMLSchema#string

P932

5387273

http://www.w3.org/2001/XMLSchema#string